On February 5, the Hurun Research Institute released the "2025 Hurun China 500," listing China's top 500 non-state-owned enterprises ranked by enterprise value.

A total of 7 companies from Chengdu made the list. Among them, Biokin Pharmaceutical entered the top 100, with its enterprise value increasing by RMB 79.5 billion, securing the 86th position on the list. This represents a rise of 56 places compared to the previous year, ranking second among the Chengdu-based companies on the list.

Furthermore, Chengdu was also listed as one of the "Most Preferred Manufacturing Bases for Hurun China 500 Enterprises," with Biokin Pharmaceutical, Eoptolink, and New Hope Group cited as representative companies.

This marks the seventh consecutive year the Hurun Research Institute has released the "Hurun China 500." The market value of listed companies is calculated based on their closing share prices as of November 14, 2025, while the valuation of non-listed companies is estimated by referencing comparable listed peers or their latest round of financing.

        "Over the past year, China's top 500 companies have achieved significant overall growth. The entry threshold has risen by nearly 30% compared to last year, and the total enterprise value has increased by nearly 40%," said Rupert Hoogewerf, Chairman and Chief Researcher of Hurun Group. He added that driven by new quality productive forces, Chinese companies have delivered impressive performances over the past year in areas such as AI computing power, consumer electronics, innovative pharmaceuticals, and entertainment, becoming a vital force propelling the high-quality development of the private economy.